COMPANY

ResVita Bio

HQ: Berkeley, CA source · resvitabio.com ↗

ResVita Bio is developing topical treatments for skin diseases using engineered bacteria that deliver therapeutic proteins to the skin, for Netherton syndrome (FDA orphan drug and rare pediatric designations, 2024) and atopic dermatitis. From company website Source · Oct 12, 2026

Keywords: synthetic biology Netherton syndrome atopic dermatitis orphan drug

Location: Berkeley, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $1M (SBIR Phase II 2R44AI179327-02A1, competing renewal, notice Jul 30, 2026). NIH RePORTER 2R44AI179327-02A1 (Jul 30, 2026)
Evidence (1 event)
- Jul 30, 2026 · NIH RePORTER 2R44AI179327-02A1
  Organization: RESVITA BIO, INC.; City/State: Berkeley, CA; Project number: 2R44AI179327-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-30; FY total cost (award amount): 999988; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Skin probiotics to treat atopic dermatitis; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Jul 30, 2026 Grant Government grant — SBIR: $999,988 (annual award, as published), announced Jul 30, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Aug 14, 2025 Grant Government grant — SBIR: $703,229 (annual award, as published), announced Aug 14, 2025. Agency: NIH/NIAMS. Source: government award database. source ↗

Funding

Last 2 years.

Jul 30, 2026 Government grant — SBIR: $999,988 (annual award, as published), announced Jul 30, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Aug 14, 2025 Government grant — SBIR: $703,229 (annual award, as published), announced Aug 14, 2025. Agency: NIH/NIAMS. Source: government award database. source ↗